Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib versus chemotherapy in advanced or metastatic BRAF V600E/K mutation-positive melanoma
2010-022838-85Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trametinib in melanoma (2 arms), sponsored by Novartis. Primary endpoint: Progression-free survival. Started Nov 2010; status: completed.
02
Drugs
trametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2010-022838-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022838-85.